^
Association details:
| Biomarker: | PD-L1 overexpression + KRAS mutation |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Verzenio (abemaciclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous Non-Small Cell Lung Cancer: A Phase 1B Study
Published date:
09/25/2021
Excerpt:
...patients with previously untreated PD-L1-positive, KRAS-mutant non-squamous metastatic NSCLC...Patients received 150mg abemaciclib every 12 hours plus 200mg pembrolizumab...The subgroup of patients in cohort A with strong PD-L1 TPS (n = 13) had an ORR of 25 30.8% (95% CI, 9.1–61.4).
DOI:
https://doi.org/10.1016/j.jtocrr.2021.100234
Trial ID:
